Tag Archives: HDV Infection

April, 2016

  • 22 April

    Eiger Biopharma Licenses an Investigational HVD Therapy from BMS

    PALO ALTO, Calif., April 20, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) announced today that it has licensed Pegylated Interferon Lambda-1a (“Lambda”), a novel, well-characterized, first in class Type III interferon to be studied as an investigational therapy for hepatitis delta virus (HDV) infection, from Bristol-Myers Squibb.  Lambda has …